Baymatob

Baymatob is a medical device company focused on improving maternal and fetal health outcomes through its AI-driven platform, Oli™. Oli is a first-in-class prognostic tool that provides early detection and monitoring of serious, treatable complications during pregnancy and labour.

Key Investment Highlights

• First-in-class maternal health platform, providing predictive, personalised care to prevent severe complications, before they occur – clinical evidence for at least 15 products on the platform
• Commercial pilot completed demonstrating Oli can improve health outcomes by 50% and save up to 30% of the $1.8B USD costs p.a. from postpartum haemorrhaging (PPH)
• Strategic relationship in place with potential acquirer – Stryker, alongside significant other strategic interest
• Leading clinical KOLs and clinical sites engaged, ready to conduct clinical trials in Australia and the USA
• Fast-track to market by FDA (granted Breakthrough Device Designation)
• Pivotal clinical trial approved to commence in Australia, ahead of USA commencement in the coming months.
• Pricing, reimbursement, willingness to adopt, and go to market strategy formed & well understood, based on commissioned work
• Female founded, female-led, women’s health business, inspired by lived experience.
• Highly experienced team – CEO, Tara Croft, instrumental in taking Nanosonics from early idea to ASX200 / Market Cap $2.4B AUD company (2007 – 2019)

Key Achievements

• FDA Breakthrough Device Designation: Oli, received the FDA Breakthrough Device Designation. This designation recognizes Oli's potential to provide more effective treatment for life-threatening conditions and grants Baymatob an expedited regulatory review path.
• Clinical Trials: Baymatob has completed a 500-patient pilot study, one of Australia's largest maternity health studies for a medical device. The study was conducted at Royal North Shore Hospital and The Royal Hospital for Women in Sydney, showing promising early results in identifying mothers at risk of PPH before bleeding starts.
• Funding and Support: Baymatob has secured significant funding to support its development and clinical trials, including from the Medical Research Future Fund (MRFF)  as part of the ANDHealth+ digital health commercialization program.
• Awards and Recognition: Baymatob was honored as the AI Innovator in Healthcare at the 2024 Australian AI Awards, recognizing their AI-driven solutions that are transforming healthcare by improving health outcomes for mothers and babies.
• CUREator+ Grant: Baymatob was selected for the CUREator+ accelerator program, funded by the Australian Government’s MRFF. This program supports digital health startups and provides Baymatob with additional resources and mentorship

Company Overview

Maternity care is stuck in the past - Mothers giving birth today are monitored with the same technology that monitored their grandmothers, when they gave birth in the 1960s. This is despite rising rates of complications, preventable harm, and soaring healthcare costs. It is time for a new standard in maternal care - powered by cutting-edge, predictive technology. The opportunity to invest in change has never been more urgent - or more promising.

Baymatob is developing a groundbreaking maternal health platform that uses wearable sensor data and AI to predict and prevent complications during pregnancy and birth. Their first focus is postpartum hemorrhage—a leading cause of maternal harm - which costs the U.S. healthcare system $1.8B annually.

The Problem

Why is Baymatob needed?

• Traditional maternal monitoring methods have not evolved significantly in over 60 years, leading to rising maternal health costs and complications.
• Some of these complications, that Baymatob seeks to address include:
  • Postpartum Hemorrhage (PPH): PPH affects 10% of all births globally and costs the US healthcare system $1.8 billion annually.
  • Pre-term Labour: Preterm births account for 10% of all births worldwide, with higher rates among certain demographics. These births cost the US healthcare system $103 billion per year.
  • Stillbirth Prevention: Stillbirth affects 1 in 175 pregnancies in the US, with 2 million stillbirths occurring globally each year.
  • Uterine Hyperstimulation and Rupture: Uterine hyperstimulation can lead to labour complications, emergency caesarean sections, and stillbirths.
• The Oli™ platform is focused on enhancing maternal and fetal health through improved monitoring and early detection of the above complications, as well as others, ultimately aiming to reduce healthcare costs and improve outcomes for mothers and babies.

The Solution

Baymatob provides an innovative solution to address the significant challenges in maternal and fetal health through their AI-driven platform.

• Oli Platform: Baymatob's Oli platform includes a novel wearable sensor that collects millions of physiological data points. These data points are processed by an AI-powered engine to generate personalized, actionable clinical insights across a range of conditions and complications.
• Early Detection and Monitoring: Oli is designed to provide early detection and monitoring of serious, treatable complications during pregnancy and labour. This includes identifying individuals at higher risk of developing PPH well before they give birth.
• Improved Health Outcomes: By providing more information earlier, Oli allows for timely clinical intervention, which can save lives and reduce irreversibly debilitating outcomes such as emergency hysterectomy (Oli has been shown to reduce emergency hysterectomies and blood transfusions by ~50%)

Market Opportunity

• Large and growing TAM: Baymatob's Oli platform has diverse revenue streams across the $5.7 billion USD maternal-fetal monitoring market globally, with strong projected growth.
• Strong early indications of clinician uptake: in a Rock Health survey, 88% of clinicians saw moderate-high value in the Oli device (50% is considered ‘enough’ market interest for commercialisation).
• Scalable Commercial Opportunity: Baymatob aims to leverage existing market opportunities and expand rapidly as a US-focused company.

Go To Market Planning

Natural group companies are logical acquirers, and Baymatob is known to several of these:

• Maternity monitoring equipment companies -  Oli as extension/replacement for current products
• Women’s Healthcare pharmaceutical companies  - Oli predicts need for and guides use of critical medicines.
• Integrated Health System Maternity Programs - Oli as foundation for expanding AI-enabled care strategies.

Commercial planning is underway, and will continue to be developed utilizing funds from this raise

Revenue Opportunity

Baymatob plans to become revenue-generating with the launch of Oli^TM’s PPH prognostic capability in 2027. The Oli^TM Platform has diverse revenue streams across the $2.9B USD maternal-fetal monitoring market globally, with strong projected growth:

NB: Projected revenue figures are estimates only and are not guaranteed. Actual results may vary significantly. Baymatob do not warrant or represent that these projections will be achieved, and accept no liability for any losses or damages resulting from reliance on them.

Management and Board

Baymatob is led by a highly experienced team including CEO, Tara Croft, instrumental in taking Nanosonics from early idea to ASX200. These include:

Tara Croft – CEO

Tara was Instrumental in the early team that scaled and grew Nanosonics to $2.4B market cap/ASX200. Led broad functions: development, regulatory approval launch & growth.

Dr Edward Evantash – Chief Medical Officer

Dr Evantash is an MD specializing in OBGYN. Expert in PPH. CMO at Alydia healthcare (acq. Organon, 2021) with novel PPH treatment, and medical leadership roles including Hologic & Materna Medical.

Penny Flicker – Director of Commercial Operations

Penny is a Medical Device/digital health expert, with broad expertise across all facets of building, developing and scaling a medical technology, commercially and technically.

Bernadette Pickering – Director of Clinical Operations

Bernadette has 20 years’ experience in global clinical research – built the clinical trials function for Cochlear. Expertise from first in human feasibility, pivotal RCTs to post market surveillance.

Rishi Ramakrishnan – Director of Technology

Rishi was the original engineer developing, the Oli^TM technology, ML algorithms and its clinical applications. Leads development of algorithms, and technology for the Oli product.

Terms of the Offer

The Company is looking to raise a minimum of $5,000,000 under the current offer at $1.91 per Series A3 Preference Share and a pre-money equity valuation of $9 million.

The offer is led by Scale – female-founder focussed fund. It has high calibre participation including Perennial, and University of Sydney.

To invest in Baymatob, OnMarket participating investors will be required to join the Scale syndicate. Investment Onboarding Document available here.

Baymatob Pty Ltd is a privately held company, and this arrangement has been made to enable to company to best administer shareholders. There are no additional fees to the investor for participating in this arrangement.

Following the receipt of their investment commitments via the OnMarket platform, investors will be granted access to the Scale platform.

GXE Pty Ltd is the Syndicate Administrator for Scale Investors. To ensure regulatory compliance and efficient communication the GXE platform is where all investor and investment information is housed.

Funds raised under this offer will be used to complete the Oli^TM pivotal clinical study, prepare an FDA file, and build accompanying commercial and operational capabilities.

Capitalisation Table

NB: This is the correct and final version of the Cap Table. It supersedes the version that is provided in the terms sheet attached.

Section 708 disclosure: The issuer of the securities is Baymatob Pty Limited. The securities to be issued are Series A3 Preference shares. The information provided on the OnMarket website has been prepared by Baymatob Pty Limited, and OnMarket makes no representation as to its accuracy or completeness.  No prospectus has been prepared and accordingly, the Offer is being made to sophisticated and professional investors only. 

The information memorandum is intended to provide potential investors with information only and does not constitute a prospectus, short form prospectus or other disclosure document as defined in the Corporations Act 2001 (Cth) (“the Act”). This document has not been lodged with the Australian Securities and Investments Commission ("ASIC") or any other government body. The offer made under this Information Memorandum is only available for persons who qualify as sophisticated (as defined in s708(8)-(10) of the Act), professional investors (as defined in s708(11) of the Act), investors to whom personal offers are made under s708(1), or investors to whom disclosure is otherwise not required under Part 6D of the Act (collectively, “Qualified Investors”).